Abeona Therapeutics Inc.
Index- P/E- EPS (ttm)-0.84 Insider Own0.30% Shs Outstand147.38M Perf Week16.50%
Market Cap25.78M Forward P/E- EPS next Y-0.23 Insider Trans-2.03% Shs Float124.15M Perf Month-33.94%
Income-84.90M PEG- EPS next Q-0.08 Inst Own24.20% Short Float3.25% Perf Quarter-26.44%
Sales3.00M P/S8.59 EPS this Y5.10% Inst Trans-12.39% Short Ratio1.99 Perf Half Y-80.33%
Book/sh0.49 P/B0.37 EPS next Y27.30% ROA-46.00% Target Price2.67 Perf Year-86.76%
Cash/sh0.31 P/C0.57 EPS next 5Y- ROE-69.90% 52W Range0.13 - 1.92 Perf YTD-46.59%
Dividend- P/FCF- EPS past 5Y-6.20% ROI-171.40% 52W High-90.62% Beta1.54
Dividend %- Quick Ratio3.30 Sales past 5Y27.50% Gross Margin- 52W Low38.14% ATR0.03
Employees90 Current Ratio3.30 Sales Q/Q0.00% Oper. Margin- RSI (14)39.51 Volatility19.38% 13.51%
OptionableYes Debt/Eq0.00 EPS Q/Q-155.80% Profit Margin- Rel Volume0.82 Prev Close0.16
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.03M Price0.18
Recom2.30 SMA20-12.93% SMA50-30.96% SMA200-71.38% Volume1,630,042 Change11.18%
Nov-11-20Upgrade Cantor Fitzgerald Neutral → Overweight $4
Sep-18-20Initiated B. Riley FBR Buy $5
Feb-10-20Initiated SVB Leerink Outperform $6
Dec-10-19Resumed Cantor Fitzgerald Neutral $2 → $4
Aug-15-19Downgrade Maxim Group Buy → Hold
Aug-12-19Downgrade Cantor Fitzgerald Overweight → Neutral $29 → $2
Jul-26-19Downgrade Mizuho Buy → Neutral $17 → $4
Jun-27-19Initiated Mizuho Buy
Oct-12-18Initiated Mizuho Buy $17
Jun-05-18Initiated Seaport Global Securities Buy $29
Nov-08-17Initiated SunTrust Buy $26
Oct-16-17Reiterated H.C. Wainwright Buy $20 → $30
Oct-11-17Reiterated Cantor Fitzgerald Overweight $21 → $34
Oct-10-17Initiated Citigroup Buy $32
Oct-05-17Reiterated Maxim Group Buy $17 → $35
Sep-15-17Initiated RBC Capital Mkts Outperform $23
Jul-18-17Reiterated Maxim Group Buy $14 → $17
Jun-22-17Resumed Jefferies Buy $22
Jan-06-17Initiated Jefferies Buy
Sep-29-16Reiterated Maxim Group Buy $8 → $14
May-13-22 07:30AM  
May-12-22 02:47PM  
May-11-22 02:28PM  
May-10-22 02:36PM  
May-06-22 03:48PM  
May-04-22 07:30AM  
May-03-22 07:00AM  
Apr-29-22 09:00AM  
Apr-19-22 10:51AM  
Mar-31-22 07:30AM  
Mar-28-22 11:20AM  
Mar-14-22 07:30AM  
Jan-25-22 10:00AM  
Dec-22-21 07:30AM  
Dec-17-21 09:00AM  
Dec-16-21 04:01PM  
Dec-02-21 07:25AM  
Nov-19-21 10:00AM  
Nov-18-21 07:30AM  
Nov-17-21 07:30AM  
Nov-16-21 07:30AM  
Nov-15-21 07:45AM  
Oct-21-21 07:30AM  
Oct-13-21 07:30AM  
Oct-12-21 07:30AM  
Sep-21-21 04:01PM  
Sep-07-21 07:30AM  
Aug-10-21 07:30AM  
Jul-28-21 04:01PM  
Jul-26-21 07:30AM  
Jul-23-21 07:30AM  
Jul-07-21 12:02PM  
Jun-14-21 10:00AM  
Jun-02-21 07:30AM  
May-26-21 07:30AM  
May-25-21 07:30AM  
May-18-21 07:30AM  
May-11-21 06:06AM  
Apr-20-21 07:30AM  
Apr-19-21 07:30AM  
Mar-25-21 07:30AM  
Mar-24-21 05:15PM  
Mar-23-21 12:41PM  
Mar-22-21 07:30AM  
Mar-11-21 11:22PM  
Feb-25-21 11:33AM  
Feb-22-21 07:30AM  
Feb-12-21 11:36AM  
Feb-02-21 07:30AM  
Jan-25-21 07:30AM  
Jan-12-21 08:50AM  
Dec-21-20 12:20PM  
Dec-14-20 09:44PM  
Dec-01-20 10:06AM  
Nov-27-20 08:25AM  
Nov-24-20 03:10PM  
Nov-18-20 11:24AM  
Nov-17-20 01:16PM  
Nov-12-20 05:21AM  
Nov-09-20 05:55PM  
Oct-27-20 06:30AM  
Oct-14-20 10:58PM  
Oct-06-20 04:01PM  
Sep-28-20 09:27AM  
Sep-18-20 11:08AM  
Sep-08-20 04:05PM  
Sep-01-20 06:29AM  
Aug-17-20 07:00AM  
Aug-10-20 04:01PM  
Aug-04-20 11:36AM  
Jul-10-20 07:30AM  
Jul-09-20 09:10AM  
Jul-08-20 07:30AM  
Jul-03-20 07:48AM  
Jun-23-20 11:59AM  
Jun-18-20 07:30AM  
Jun-17-20 07:30AM  
Jun-08-20 09:11AM  
May-28-20 11:30AM  
May-08-20 12:58PM  
May-07-20 01:59PM  
May-06-20 04:14PM  
Apr-29-20 11:08AM  
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
O'Malley Brendan M.SVP, General CounselDec 06Sale0.578,8805,035204,750Dec 08 07:05 PM
O'Malley Brendan M.SVP, General CounselNov 05Sale0.898,8807,894213,630Nov 05 07:00 PM
O'Malley Brendan M.SVP, General CounselOct 11Sale0.9025,73423,271222,510Oct 13 07:08 PM
O'Malley Brendan M.SVP, General CounselOct 08Sale1.0522,76323,915248,244Oct 08 08:31 PM
CARR EDWARDChief Financial OfficerOct 08Sale1.0529,12230,596400,169Oct 08 08:29 PM
Wider ToddDirectorOct 07Sale0.9725,00024,1500Oct 08 08:33 PM
O'Malley Brendan M.SVP, General CounselOct 05Sale1.052,4472,569271,007Oct 08 08:31 PM
Amoroso MichaelChief Executive OfficerSep 30Sale1.0945,40949,382604,637Oct 04 04:06 PM